Broncus Holding Corp
HKEX:2216
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.46
0.97
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Broncus Holding Corp
Free Cash Flow
Broncus Holding Corp
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
B
|
Broncus Holding Corp
HKEX:2216
|
Free Cash Flow
-$26.8m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
A
|
APT Medical Inc
SSE:688617
|
Free Cash Flow
ÂĄ487m
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Free Cash Flow
ÂĄ1.7B
|
CAGR 3-Years
42%
|
CAGR 5-Years
67%
|
CAGR 10-Years
49%
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Free Cash Flow
ÂĄ12.5B
|
CAGR 3-Years
22%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
||
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
Free Cash Flow
ÂĄ926.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Free Cash Flow
-ÂĄ943.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Broncus Holding Corp
Glance View
Broncus Holding Corp. engages in provision of interventional diagnosis and therapeutics solutions. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2021-09-24. The firm's business includes providing diagnostic solutions, lung cancer treatment solutions, chronic obstructive pulmonary disease solutions and navigation platforms. The diagnostic solutions pruducts include FleXNeedle, ATV Sheath, ATV Balloon and others. The lung cancer treatment solutions products include InterVapor for lung cancer, H-Marker and others. The chronic obstructive pulmonary disease (COPD) solutions products include InterVapor for COPD and TLD Ablation System. The navigation platform products include Lungpoint, Lungpro, New Generation Navigation Platform and others.
See Also
What is Broncus Holding Corp's Free Cash Flow?
Free Cash Flow
-26.8m
USD
Based on the financial report for Dec 31, 2023, Broncus Holding Corp's Free Cash Flow amounts to -26.8m USD.
What is Broncus Holding Corp's Free Cash Flow growth rate?
Free Cash Flow CAGR 3Y
-17%
Over the last year, the Free Cash Flow growth was 16%. The average annual Free Cash Flow growth rates for Broncus Holding Corp have been -17% over the past three years .